 |
BioWorld-International-2009-06-24
Compound May Ease Pain Without the Side Effects
Chroma Pact with GSK Carries $1B Potential
LONDON - Chroma Therapeutics Ltd. landed a deal boasting a headline value of $1 billion with GlaxoSmithKline (GSK) plc, in which Chroma will apply its chemical motif technology for targeting small molecules directly into macrophages, to develop treatments for autoimmune and other inflammatory diseases. (BioWorld International)